BIOCARDIA INC (BCDA)
US09060U6064 - Common Stock
BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family
SUNNYVALE, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the...
BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure
Next PMDA Consultation after Review of CardiAMP HF Trial Data...
BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results
SUNNYVALE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the...
BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure
BioCardia announced today the completion of its last protocol specified follow-up visit in CardiAMP HF multi-center trial....
BioCardia Regains Full Compliance with Nasdaq Listing Requirements
SUNNYVALE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the...
BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
SUNNYVALE, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the...
BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
SUNNYVALE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the...
BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family
SUNNYVALE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the...
FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment
BioCardia announced today that the FDA has approved an important protocol amendment for the CardiAMP Heart Failure II Trial, its confirmatory Phase 3...
BCDA Stock Earnings: BioCardia Reported Results for Q2 2024
BioCardia just reported results for the second quarter of 2024.
BCDA Stock Earnings: BioCardia Reported Results for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioCardia (NASDAQ:BCDA) just reported results for the second quarter of 2024.Bi...
BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results
SUNNYVALE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the...
BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application
SUNNYVALE, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Pre-market stock movers are worth diving into on Monday and we have all of the latest news worth knowing about this morning!
BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach
BioCardia announces that the USPTO has granted Patent No: 11,986,611 titled “Radial and Transendocardial Delivery Catheter,” with a 2036 expiration date....
BCDA Stock Earnings: BioCardia Misses EPS, Misses Revenue for Q2 2023
BCDA stock results show that BioCardia missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2023.
BCDA Stock Earnings: BioCardia Misses EPS, Misses Revenue for Q2 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioCardia (NASDAQ:BCDA) just reported results for the second quarter of 2023.Bi...
BioCardia Announces Reverse Stock Split
SUNNYVALE, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the...
BCDA Stock Earnings: BioCardia Reported Results for Q1 2024
BioCardia just reported results for the first quarter of 2024.
BCDA Stock Earnings: BioCardia Reported Results for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioCardia (NASDAQ:BCDA) just reported results for the first quarter of 2024.Bio...
BioCardia Reports First Quarter 2024 Business Highlights and Financial Results
SUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the...
BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024
SUNNYVALE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the...
BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes
SUNNYVALE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the...
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort
Call Scheduled for Study Clinical Leadership to Discuss Results and Details on Pivotal Randomized Trial...